| 1 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
According to the study on AI in medical imaging, the main goal of AI tools is to enhance the accuracy of diagnoses (e.g., detecting diseases in scans) and ultimately improve treatment decisions and patient health outcomes. |
Clinical Decision Support Systems (CDSS)
AI-Assisted Diagnostic Enhancement |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Acts as a second medical opinion |
|
The article highlights that one of the key benefits of AI in radiology is its role as a second opinion to assist radiologists in making more accurate and confident diagnoses. |
Clinical Decision Support
AI-Assisted Diagnosis |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
According to the article, AI literacy refers to how well healthcare professionals understand how AI works, its capabilities, limitations, and how to use it appropriately in medical imaging. |
Technology Acceptance Model (TAM)
AI Literacy in Health Informatics |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
The color of the AI machines |
|
The article discusses several important factors that influence how healthcare professionals accept AI, including:
– Trust in AI systems
– Integration with clinical workflows
– Understanding how AI works
– Openness to adopting new technologies
But it does not mention the color of AI machines, which is irrelevant to professional acceptance. |
Technology Acceptance Model (TAM)
Human Factors in Health Technology Adoption |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Affects healthcare professionals’ decisions to use AI |
|
The article explains that social influence—such as the opinions of colleagues, supervisors, or the broader professional community—impacts whether healthcare professionals are willing to adopt and trust AI systems in their clinical work. |
Technology Acceptance Model (TAM)
Social Influence in Technology Adoption |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a perceived threat regarding AI usage in healthcare settings?
|
Concerns about replacing healthcare professionals |
|
The article notes that one major perceived threat is the fear that AI might replace human roles, especially among radiologists and other healthcare professionals, leading to job insecurity and resistance to adoption. |
Technology Displacement Anxiety
Human–AI Collaboration Concerns |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Designing human-centred AI systems |
|
The article emphasizes that for AI to be widely accepted in healthcare, it must be human-centred—meaning it should support, not replace, healthcare professionals, and be easy to understand, trustworthy, and well-integrated into their workflows. |
Human-Centered Design
User Acceptance in Health Technology |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
According to the article, the ‘system usage’ category refers to how AI systems fit into existing clinical workflows, whether they offer clear value, and how easy they are to use in daily practice. |
System Usability Theory
Workflow Integration in Health IT |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
The article explains that ethicality plays a key role in AI acceptability. Healthcare professionals are more likely to adopt AI if they believe it aligns with their ethical standards, such as patient safety, fairness, and transparency. |
Ethical Alignment in Technology Adoption
Value-Based Acceptance Models |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
The article emphasizes that future studies on AI acceptability should focus more on the real-world experiences of users, including how well AI integrates into clinical workflows and supports healthcare professionals in practice. |
User-Centered Research
Human–Technology Interaction |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
The primary objective of using human embryonic stem cells (hESCs) in treating Parkinson’s disease is to replace the dopamine-producing neurons that are lost or damaged in the brains of patients with the condition. |
Cell Replacement Therapy
Stem Cell-Based Regenerative Medicine |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Monkeys |
|
The STEM-PD study tested the safety and efficacy of human embryonic stem cell-derived dopamine neurons in non-human primates (monkeys), which closely mimic the human brain in structure and function—making them ideal for Parkinson’s disease research. |
Preclinical Testing in Non-Human Primates
Translational Neuroscience |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
12 months |
|
According to the article on the STEM-PD study, the preclinical safety study in rats lasted 12 months to monitor long-term effects such as tumor formation, graft survival, and safety of the implanted stem cell-derived dopamine neurons. |
Long-Term Toxicology Studies
Regulatory Requirements for Cell-Based Therapies |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I/IIa |
|
The article on STEM-PD states that the product is advancing to a Phase I/IIa clinical trial, which combines early safety evaluation (Phase I) with preliminary efficacy assessment (Phase IIa) in patients with Parkinson’s disease. |
Clinical Trial Phases
Early-Phase Translational Research |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How is the STEM-PD product manufactured?
|
Under GMP-compliant conditions |
|
The article states that the STEM-PD product was manufactured under Good Manufacturing Practice (GMP)-compliant conditions to ensure safety, quality, and consistency—an essential requirement for clinical-grade stem cell therapies.
|
GMP (Good Manufacturing Practice)
Regulatory Standards in Cell Therapy Production |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
The article reports that in the 12-month preclinical safety study in rats, the STEM-PD product showed no signs of toxicity, tumor formation, or adverse effects, confirming its safety for clinical use. |
Preclinical Toxicology
Tumorigenicity Assessment in Cell Therapy |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
Transplanted cells reversed motor deficits in rats. |
|
The efficacy study showed that the STEM-PD cells, once transplanted into Parkinson’s model rats, differentiated into dopamine neurons and successfully reversed motor symptoms, demonstrating therapeutic potential. |
Cell Replacement Therapy
Functional Recovery in Preclinical Models |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
GIRK2 and ALDH1A1 |
|
The article notes that GIRK2 and ALDH1A1 were used as specific markers to assess the purity and identity of the dopamine neurons in the STEM-PD product batch, as they are associated with A9-type dopaminergic neurons—the type lost in Parkinson’s disease. |
Cell Identity Markers in Dopaminergic Neuron Differentiation
Quality Control in Stem Cell Therapy |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They are used in cell patterning for specific neural fates. |
|
In the manufacturing of the STEM-PD product, growth factors like FGF8b and SHH (Sonic Hedgehog) are used during differentiation to guide stem cells toward becoming midbrain dopaminergic neurons, which are the type lost in Parkinson’s disease. |
Directed Differentiation in Stem Cell Biology
Neural Patterning via Morphogen Signaling |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Recovery of motor function |
|
The preclinical efficacy trials of STEM-PD in rats focused on whether the transplanted dopamine neurons could restore motor function—the primary symptom affected in Parkinson’s disease. The results showed significant improvement in motor deficits, confirming therapeutic potential. |
Functional Outcome Measures in Parkinson’s Models
Motor Behavior Assessment in Preclinical Neuroscience |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|